{'fraction_non_alphanumeric': 0.021963824289405683, 'fraction_numerical': 0.02454780361757106, 'mean_word_length': 5.007751937984496, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
FAILURE OF LONG‐TERM CYPROHEPTADINE THERAPY IN LOWERING GROWTH HORMONE LEVELS IN ACROMEGALY

Basal and post‐glucose growth hormone (GH) responses were evaluated in 10 acromegalics receiving cyproheptadine (cypro) 4 mg 6 hourly at 2 and 21 days after initiating therapy. Of the 10 patients, six had macroadenomas with varying degree of suprasellar extensions, one a microadenoma and three had persistent hypersomatotropism despite pituitary adenomectomy due to residual tumour. The basal and post‐glucose GH showed no significant change in all, except one with a pituitary microadenoma. His GH was reduced from 680 to 108 mU/L on the second and 82 mU/I on the 21st day of cypro therapy. These data do not suggest any therapeutic role of cypro in the management of acromegaly.